Kyowa Kirin Overview

  • Year Founded
  • 1949

Year Founded

  • Status
  • Public

  • Employees
  • 3,503

Employees

  • Stock Symbol
  • 4151

Stock Symbol

  • Investments
  • 13

  • Share Price
  • $15.93
  • (As of Friday Closing)

Kyowa Kirin General Information

Description

Kyowa Kirin Co Ltd is engaged in research, development, manufacturing, sales, import and export of prescription pharmaceuticals. Its products include KHK4083/AMG 451, rocatinlimab; ziftomenib; OTL-203 KK8398, infigratinib; KHK4951, tivozanib; OTL-201; KK4277; KK2260; KK2269; KK2845; and KK8123.

Contact Information

Formerly Known As
Kyowa Hakko Kirin
Ownership Status
Publicly Held
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Otemachi Financial City Grand Cube
  • 1-9-2 Otemachi, Chiyoda-ku
  • Tokyo, 100-0004
  • Japan
+81
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
TKS
Corporate Office
  • Otemachi Financial City Grand Cube
  • 1-9-2 Otemachi, Chiyoda-ku
  • Tokyo, 100-0004
  • Japan
+81

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Kyowa Kirin Stock Performance

As of 20-Nov-2026, Kyowa Kirin’s stock price is $15.93. Its current market cap is $8.34B with 524M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$15.93 $16.10 $13.43 - $18.68 $8.34B 524M 1.79M $1.01

Kyowa Kirin Financials Summary

As of 30-Jun-2026, Kyowa Kirin has a trailing 12-month revenue of $3.43B.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 6,986,570 7,142,692 6,108,979 6,459,799
Revenue 3,431,069 3,319,529 3,272,126 3,147,336
EBITDA 810,561 750,316 752,739 808,902
Net Income 526,757 447,926 395,316 577,808
Total Assets 6,984,068 7,082,281 6,797,181 7,274,637
Total Debt 168,040 198,936 183,067 171,928
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Kyowa Kirin Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Kyowa Kirin‘s full profile, request access.

Request a free trial

Kyowa Kirin Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Kyowa Kirin Co Ltd is engaged in research, development, manufacturing, sales, import and export of prescription pharmace
Drug Discovery
Tokyo, Japan
3,503 As of 2025

Osaka, Japan
 

Osaka, Japan
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Kyowa Kirin Competitors (33)

One of Kyowa Kirin’s 33 competitors is Shionogi, a Corporation company based in Osaka, Japan.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Shionogi Corporation Osaka, Japan
Sumitomo Pharma Corporation Osaka, Japan
Taiho Pharma Corporation Tokyo, Japan
Hoechst Pakistan Corporate Backed or Acquired Karachi, Pakistan
Cipla Corporation Mumbai, India
You’re viewing 5 of 33 competitors. Get the full list »

Kyowa Kirin Patents

Kyowa Kirin Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026177128-A1 Fusion protein Pending 18-Feb-2025
WO-2026141571-A1 Compound with slc15a4 inhibitory activity Pending 26-Dec-2024
WO-2026084068-A1 Antibody that binds to human tpor Pending 18-Oct-2024
WO-2026034490-A1 Compound having slc15a4 inhibitory activity Pending 06-Aug-2024
WO-2026020076-A1 Method for treating prurigo nodularis Pending 18-Jul-2024 C07K16/2878
To view Kyowa Kirin’s complete patent history, request access »

Kyowa Kirin Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Kyowa Kirin Investments & Acquisitions (13)

Kyowa Kirin’s most recent deal was a Early Stage VC with Link Cell Therapies for . The deal was made on 28-Sep-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Link Cell Therapies 28-Sep-2026 Early Stage VC Drug Discovery
Stratus Therapeutics 04-Mar-2025 Early Stage VC Drug Discovery
Orchard Therapeutics 24-Jan-2024 Merger/Acquisition Biotechnology
Grünenthal Meds 02-Aug-2023 Joint Venture Other Pharmaceuticals and Biotechnology
Ring Therapeutics 09-Mar-2023 Later Stage VC Drug Discovery
You’re viewing 5 of 13 investments and acquisitions. Get the full list »

Kyowa Kirin ESG

Risk Overview

Risk Rating

Updated November, 17, 2026

22.07 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Kyowa Kirin’s complete esg history, request access »

Kyowa Kirin Exits (5)

Kyowa Kirin’s most recent exit was on 04-Mar-2025 from Stratus Therapeutics. The exit was categorized as with 4 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
Stratus Therapeutics 04-Mar-2025 Completed
  • 4 buyers
Grünenthal Meds 02-Aug-2023 Completed
  • 2 buyers
Ardelyx 25-Nov-2019 Completed
TargaZyme 01-Jan-2017 Completed
  • 7 buyers
Mohan Medicine Research Institute Company 01-Jan-1990 Merger/Acquisition Completed
To view Kyowa Kirin’s complete exits history, request access »

Kyowa Kirin Affiliates

Subsidiaries (5)

Name Industry Location Year Founded
Kyowa Kirin Frontier Kk Tokyo, Japan 2017
Kyowa Kirin International Galashiels, United Kingdom 1995
Kyowa Hakko Kirin Korea Seoul, South Korea 1991
Kyowa Pharma Chemical Takaoka City, Japan 1946
Kyowa Kirin Plus Co. Tokyo, Japan

Kyowa Kirin FAQs

  • When was Kyowa Kirin founded?

    Kyowa Kirin was founded in 1949.

  • Where is Kyowa Kirin headquartered?

    Kyowa Kirin is headquartered in Tokyo, Japan.

  • What is the size of Kyowa Kirin?

    Kyowa Kirin has 3,503 total employees.

  • What industry is Kyowa Kirin in?

    Kyowa Kirin’s primary industry is Drug Discovery.

  • Is Kyowa Kirin a private or public company?

    Kyowa Kirin is a Public company.

  • What is Kyowa Kirin’s stock symbol?

    The ticker symbol for Kyowa Kirin is 4151.

  • What is the current stock price of Kyowa Kirin?

    As of 20-Nov-2026 the stock price of Kyowa Kirin is $15.93.

  • What is the current market cap of Kyowa Kirin?

    The current market capitalization of Kyowa Kirin is $8.34B.

  • What is Kyowa Kirin’s current revenue?

    The trailing twelve month revenue for Kyowa Kirin is $3.43B.

  • Who are Kyowa Kirin’s competitors?

    Shionogi, Sumitomo Pharma, Taiho Pharma, Hoechst Pakistan, and Cipla are some of the 33 competitors of Kyowa Kirin.

  • What is Kyowa Kirin’s annual earnings per share (EPS)?

    Kyowa Kirin’s EPS for 12 months was $1.01.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process